ONWARDS 6: Phase 3 RCT exploring once-weekly insulin icodec versus once-daily degludec as basal-bolus regimen in T1D
In this medfyle
ONWARDS 6 is thought to be the first trial of its kind to report outcomes following treatment with a once-weekly basal insulin in people with T1D. Results showed noninferiority of once-weekly insulin icodec to once-daily insulin degludec, which could help reduce the treatment burden in T1D, but more work is needed to explore the potential of once-weekly dosing.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, Mathieu C, Rosenstock J, Woo V, Klonoff DC. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023 Nov 4;402(10413):1636-1647. doi: 10.1016/S0140-6736(23)02179-7. Epub 2023 Oct 17. PMID: 37863084.
The summary content was prepared by Marie Farrow for Medfyle, and reviewed by Marco Comoglio, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
